Core Insights - Viemed Healthcare is focused on home-based respiratory care, emphasizing a model that reduces hospital visits and readmissions while managing complex respiratory patients [3][4][20] Financial Performance - In 2025, Viemed reported over $270 million in revenue and $28 million in free cash flow, maintaining a net debt-free status [2][14] - The company has guided for 2026 revenue between $310 million and $320 million, with EBITDA projected at $65 million to $69 million [16] - Viemed has achieved a 26% compound annual growth rate (CAGR) since going public, with over 172,000 patients under care [2][7] Market Opportunity - There are approximately 1.25 million Medicare candidates for complex respiratory care, with only about 70,000 currently treated, indicating a penetration rate of roughly 6% [5][7] - The U.S. has around 25 million people with Chronic Obstructive Pulmonary Disease (COPD), with about 2.5 million at the most severe level, representing a significant market opportunity for Viemed [7] Service Diversification - Viemed has diversified its service offerings, with ventilation revenue decreasing from 87% in 2019 to 48% today, while sleep services now account for 21% of net revenue [6][11] - The company has expanded into maternal health, staffing, and other respiratory services, with a notable 62% growth in CPAP patients in 2025 [10][12] Regulatory Environment - Management highlighted supportive regulatory changes, including a new ventilator National Coverage Determination (NCD) that clarifies coverage requirements and reduces reimbursement uncertainty [21][20] - Recent reimbursement trends have been linked to Consumer Price Index (CPI) increases, with expectations for further adjustments in the coming years [22] Technology and Operational Model - Viemed employs in-house technology for remote patient monitoring and telehealth interactions, which has shown to reduce emergency room visits and hospitalizations [8][9] - The company's operating model is lean and scalable, relying on a mobile workforce rather than traditional retail locations [9]

Viemed Healthcare Conference Summary Company Overview - **Company**: Viemed Healthcare (NasdaqCM: VMD) - **Market Cap**: Approximately $350 million [3] - **Patient Base**: Over 172,000 patients across 50 states, with significant coverage in 37-38 states [1] Industry Insights - **Core Services**: Complex respiratory services, sleep platform, maternal health, and staffing divisions [1] - **Market Penetration**: - COPD market penetration is around 10% [3] - Sleep business penetration is 20% or less [3] - Overall market share for Viemed in complex respiratory is approximately 14% [6] Financial Performance - **Revenue Growth**: - 2025 revenue was over $270 million, with a 21% growth year-over-year [26] - Projected revenue for 2026 is between $310 million and $320 million [30] - **EBITDA**: Over $60 million in 2025, with guidance for 2026 between $65 million and $69 million [26][30] - **Free Cash Flow**: Generated $28 million in free cash flow in 2025, with expectations for growth in 2026 [2][32] - **Debt Status**: Company remains debt-free on a net basis [26] Growth Strategy - **Organic Growth**: - Company has a 26% CAGR since public inception [2] - Focus on densifying existing markets and expanding into new territories [18] - **M&A Strategy**: - Selective acquisitions aimed at enhancing organic growth [18] - Recent acquisitions include H&P and Lehan's Medical Equipment, which have contributed to growth in maternal health and sleep sectors [20][21] Product Diversification - **Service Mix**: - Ventilators now represent 48% of the business, down from 87% in 2019 [13] - Sleep therapy has grown to 21% of revenue, with a 62% growth rate in CPAP sales [15] - Maternal health now accounts for 6% of revenue, with a 100% growth rate in 2025 [16] - **Technology Utilization**: In-house technology enhances patient care and operational efficiency, including telehealth features for real-time interaction with respiratory therapists [7][9] Regulatory Environment - **Favorable Regulations**: - Exclusion from competitive bidding provides stability [21] - New National Coverage Determinations (NCD) for ventilators clarify treatment rules, reducing ambiguity for payers [23] - **Aging Population**: The demographic trend of baby boomers turning 65 at a rate of 10,000 per day supports demand for home healthcare services [4] Key Performance Metrics - **Growth Metrics**: - 2025 growth rates: - Sleep: 62% - Resupply: 49% - Airway clearance: 18% - Maternal health: 100% [15][16] - **Market Dynamics**: - The company is positioned to capture a significant share of the underserved COPD and sleep apnea markets, with a total addressable market of over 30 million patients for sleep apnea [15][38] Conclusion - **Investment Thesis**: Viemed Healthcare demonstrates strong growth potential through its diversified service offerings, robust financial performance, and favorable regulatory environment, making it an attractive investment opportunity in the healthcare sector [36]

LAFAYETTE, LA / ACCESS Newswire / March 16, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, today announced it will present and host one-on-one meetings with investors at Sidoti's Small-Cap Virtual Investor Conference, taking place on March 18-19, 2026. The presentation will begin at 1:45 p.m. ...

Viemed Healthcare (VMD) demonstrates strong technical momentum and is trading at a new 2-year high. Shares are up more than 30% over the past 52 weeks. VMD maintains a 100% “Buy” technical opinion from Barchart. I see VMD as an attractive investment opportunity, combining strong growth, profitability, and technical strength at a $355 million market cap. Today’s Featured Stock Valued at $355 million, Viemed Healthcare (VMD) is a home medical equipment supplier which provides post-acute respirato ...

Core Insights - Viemed Healthcare, Inc. reported a 21% year-over-year growth in net revenue for FY25, reaching $270.3 million, with a net income of $14.9 million and a record adjusted EBITDA of $61.4 million [1] - The growth was driven by strong platform momentum, contributions from Lehan's, and a broader shift towards in-home care and increased adoption of sleep/resupply services [1] - A key challenge faced was the updated National Coverage Determination (NCD), which introduced additional documentation requirements and tightened coverage criteria, temporarily affecting ventilator patient growth [1] - Despite the challenges, reimbursement levels remained unchanged, and ventilator activity has begun to normalize [1] - Viemed ended FY25 with free cash flow increasing by 141% year-over-year [1] Industry Trends - The shift towards sleep and resupply services is enhancing recurring revenue quality and reducing regulatory sensitivity [8] - Lehan's acquisition is expected to broaden commercial exposure, diversify payors, and extend the growth runway for Viemed [8] - Despite margin mix pressures, the guidance for FY26 and current valuation indicate that durable growth potential may be undervalued [8]

Financial Data and Key Metrics Changes - For the fourth quarter, revenue was $76.2 million, an increase of 26% year-over-year. For the full year, revenue totaled $270.3 million, up approximately 21% compared to 2024 [18] - Adjusted EBITDA for the fourth quarter was $18.2 million, with a full-year record of $61.4 million, representing a margin of approximately 22.7% [21] - Free cash flow totaled $28.1 million for the year, more than doubling from $11.6 million in 2024 [22] Business Line Data and Key Metrics Changes - Equipment and supply sales increased by $19.4 million or approximately 63% year-over-year, driven by sleep resupply and maternal health contributions [19] - Ventilator rentals increased by $12.2 million, or roughly 10%, reflecting higher patient volumes [20] - PAP therapy patient count reached 34,528, representing growth of 62% year-over-year, with new sleep patient setups increasing 70% compared to the prior year [10] Market Data and Key Metrics Changes - Maternal health contributed approximately $9 million to revenue in 2025, strengthening diversification and reducing concentration on Medicare [14] - The company ended the year with 1,382 employees, reflecting disciplined workforce growth [5] Company Strategy and Development Direction - The company aims to build a cash-generating home care platform with multiple growth engines, focusing on high-touch clinical models and technology-enabled approaches [4] - Maternal health is viewed as a scalable extension of the platform and an important long-term growth opportunity [15] - The company is investing in compliance capabilities and operational efficiencies to navigate regulatory changes effectively [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity, citing strong early signals in the business as they enter 2026 [4] - The updated National Coverage Determination (NCD) is expected to reduce uncertainty and position the company favorably in the market [8] - The company anticipates net revenue in the range of $310 million to $320 million for 2026, representing approximately 17% year-over-year growth [26] Other Important Information - The company has authorized a new share repurchase program for 2026, reflecting confidence in cash flows and long-term outlook [24] - The balance sheet shows $13.5 million in cash and approximately $46 million available under credit facilities, with effectively no net debt [23] Q&A Session Summary Question: What is the top priority for the Lehan's acquisition expansion? - Management indicated that expanding the payer network is the top priority, along with training sales personnel to support growth [33][34] Question: How comfortable is the sales force with training and expansion? - Management confirmed that cross-training of sales representatives is underway, with a focus on integrating new product lines into existing sales strategies [36][38] Question: How will margin stability be maintained with a diversified revenue stream? - Management noted that scalability in general and administrative expenses, along with increased transaction volumes, will help maintain margin stability [39][40] Question: What are the key assumptions underlying the current revenue guidance? - Management clarified that while vent growth is not expected to be aggressive due to NCD adjustments, significant growth is anticipated in sleep and maternal health segments [46][47] Question: How does the reduction in respiratory therapists affect service revenue? - Management explained that the number of respiratory therapists is driven by patient volumes and that they expect growth in both therapists and patient volumes in 2026 [48]

Financial Data and Key Metrics Changes - For the fourth quarter, revenue was $76.2 million, an increase of 26% year-over-year. For the full year, revenue totaled $270.3 million, up approximately 21% compared to 2024 [18] - Adjusted EBITDA for the fourth quarter was $18.2 million, with a full-year record of $61.4 million, representing a margin of approximately 22.7% [21] - Free cash flow totaled $28.1 million for the year, more than doubling from $11.6 million in 2024 [22] Business Line Data and Key Metrics Changes - Equipment and supply sales increased by $19.4 million or approximately 63% year-over-year, driven by sleep resupply and maternal health contributions [19] - Ventilator rentals increased by $12.2 million, or roughly 10%, reflecting higher patient volumes [20] - PAP therapy patient count reached 34,528, representing growth of 62% year-over-year, with new sleep patient setups increasing 70% compared to the prior year [10] Market Data and Key Metrics Changes - Maternal health contributed approximately 3% of revenue in 2025, with $9 million associated with maternal health products [14] - The diversification of revenue streams is evident, with ventilation revenue decreasing from 56% in 2024 to 51% in 2025, while sleep increased from 16% to 20% [20] Company Strategy and Development Direction - The company aims to build a cash-generating home care platform with multiple growth engines, focusing on high-touch clinical models and technology-enabled approaches [4] - Maternal health is viewed as a scalable extension of the platform and an important long-term growth opportunity [15] - The company is prioritizing organic growth and evaluating disciplined, accretive acquisition opportunities while returning capital to shareholders through share repurchases [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity, noting strong early signals in the business as they enter 2026 [4] - The company expects net revenue in the range of $310 million to $320 million for 2026, representing approximately 17% year-over-year growth [26] - Management anticipates a return to a more normalized quarterly growth pattern beginning in the second quarter of 2026 [27] Other Important Information - The company ended the year with $13.5 million in cash and approximately $46 million available under existing credit facilities, effectively having no net debt [23] - The company has begun reducing debt associated with the Lehan acquisition, supported by ongoing cash generation [24] Q&A Session Summary Question: What is the top priority for the Lehan acquisition expansion? - Management indicated that expanding the payer network is the top priority, alongside training sales staff to support growth [33][34] Question: How does the sales force feel about training and expansion? - Management confirmed that cross-training of sales representatives is underway, with a focus on integrating new product lines into existing sales efforts [36][38] Question: How will margin stability be maintained with a diversified revenue stream? - Management noted that scalability in G&A and technology improvements will help maintain margins, despite the challenges of diversifying revenue streams [39][40] Question: What are the key assumptions underlying the current revenue guidance? - Management clarified that they are not forecasting rapid growth in ventilators due to the NCD transition but expect significant growth in sleep and maternal health segments [46][47] Question: How does the reduction in respiratory therapists affect service revenue? - Management explained that the number of respiratory therapists is driven by patient volumes and that they expect growth in 2026 as patient numbers increase [48]

Financial Data and Key Metrics Changes - In Q4 2025, revenue reached $76.2 million, a 26% increase year-over-year, while full-year revenue totaled $270.3 million, up approximately 21% compared to 2024 [18] - Adjusted EBITDA for Q4 was $18.2 million, with a record full-year Adjusted EBITDA of $61.4 million, representing a margin of approximately 22.7% [20][21] - Free cash flow more than doubled year-over-year to $28.1 million, with Q4 free cash flow at $10.8 million [22][29] Business Line Data and Key Metrics Changes - Equipment and supply sales increased by $19.4 million or approximately 63% year-over-year, driven by growth in sleep resupply and maternal health from the Lehan acquisition [19] - Ventilator rentals increased by $12.2 million, or roughly 10%, reflecting higher patient volumes [19] - PAP therapy patient count reached 34,528, representing a 62% year-over-year growth, while resupply patients increased by 49% year-over-year [10][11] Market Data and Key Metrics Changes - The company noted a significant long-term opportunity in in-home ventilation, despite a moderation in patient growth due to updated National Coverage Determination (NCD) requirements [6][8] - The maternal health segment contributed approximately 3% of revenue in 2025, with expectations for significant growth as the company expands its payer network [14][19] Company Strategy and Development Direction - The company aims to build a diversified home care platform with multiple growth engines, focusing on high-touch clinical models and technology-enabled approaches [4][10] - Maternal health is viewed as a scalable extension of the platform and a long-term growth opportunity, with plans to expand beyond the original footprint of the Lehan acquisition [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity, citing strong early signals in the business and a solid foundation for growth due to regulatory clarity [4][10] - The company anticipates 2026 net revenue in the range of $310 million to $320 million, representing approximately 17% year-over-year growth, with Adjusted EBITDA guidance of $65 million to $69 million [25][26] Other Important Information - The company ended the year with $13.5 million in cash and approximately $46 million available under credit facilities, effectively having no net debt [23][29] - A new share repurchase program for 2026 was authorized, reflecting confidence in cash flows and long-term outlook [24][29] Q&A Session Summary Question: What is the top priority for the Lehan acquisition expansion? - Management indicated that expanding the payer network is the top priority, along with training sales staff to support growth [34] Question: How does the company assess the need to add or reduce respiratory therapist capacity? - The number of respiratory therapists is driven by patient volumes, and management expects growth in 2026 as patient numbers increase [50] Question: What are the key assumptions underlying the current revenue guidance? - Management noted that while vent growth is not forecasted to be aggressive due to NCD adjustments, significant growth is expected in sleep and maternal health segments [48]

March 4, 2026 Financial Supplement Fourth Quarter & Full Year 2025 This Financial Supplement contains non-GAAP financial guidance. There is no reliable or reasonably estimable comparable GAAP measure for the Company's non-GAAP financial guidance because the Company is not able to reliably predict the impact of certain items that typically have one or more of the following characteristics: highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indic ...

Financial Performance - For the year ended December 31, 2025, Viemed generated revenues of $270.3 million, a 20.5% increase from $224.3 million in 2024, with net income rising to $15.4 million from $11.4 million[191]. - For the year ended December 31, 2025, total revenue was $270.3 million, an increase of $46.0 million (20.5%) compared to 2024[210]. - Net income for the year ended December 31, 2025, was $15.4 million, reflecting a $4.0 million (34.8%) increase from 2024, with a net income margin of 5.7%[225]. - Net income for 2025 was $15,376,000, an increase of 34.5% from $11,409,000 in 2024 and 50.5% from $10,243,000 in 2023[268]. - The company achieved a net income of $15.4 million in 2025, up 35.5% from $11.4 million in 2024[264]. - Basic earnings per share for 2025 was $0.38, compared to $0.29 in 2024 and $0.27 in 2023[379]. - The diluted earnings per share for 2025 was $0.37, an increase from $0.28 in 2024 and $0.25 in 2023[379]. Revenue Breakdown - Revenue from the rental and sale of home medical equipment accounted for 90.8% of total revenue in 2025, compared to 91.0% in 2024[191]. - Ventilator rentals represented 50.6% of total revenue in 2025, down from 55.6% in 2024[187]. - Ventilator rental revenue increased by $12.2 million (9.8%) in 2025, driven by higher patient volumes and demand for ventilation services[211]. - Equipment and supply sales revenue surged by $19.4 million (62.7%), largely due to the success of the sleep resupply program and maternal health offerings from the Lehan acquisition[211]. - Revenue from Medicare as a percentage of total revenue decreased to 38% in 2025 from 41% in 2024 and 44% in 2023[298]. Operational Metrics - The company employed 401 licensed respiratory therapists (RTs) as of December 31, 2025, representing approximately 29% of the total workforce[188]. - The number of active ventilator patients at the end of Q4 2025 was 12,259, a slight decrease from 12,372 in Q3 2025[205]. - Viemed's adjusted EBITDA for Q4 2025 was $18.2 million, an increase from $16.1 million in Q3 2025[205]. - The company expects continued growth and improved operating efficiencies, although gross margin may fluctuate based on revenue mix changes[214]. Expenses and Costs - Selling, general and administrative expenses totaled $121.4 million, an increase of $15.2 million (14.3%) from 2024, but as a percentage of revenue improved to 44.9%[215]. - Research and development costs were $3.0 million, a slight decrease of $0.1 million (1.7%) from 2024, with expectations to remain consistent in 2026[218]. - Stock-based compensation increased to $9.1 million, up $2.8 million (45.3%) from 2024, reflecting a focus on employee retention and long-term incentives[219]. - Interest expense for 2025 was $1.2 million, an increase of $0.4 million from 2024, primarily due to debt issued for the Lehan acquisition[223]. Cash Flow and Liquidity - Cash and cash equivalents decreased to $13.5 million as of December 31, 2025, down from $17.5 million at the end of 2024[229]. - Net cash provided by operating activities for the year ended December 31, 2025 was $51.916 million, compared to $39.089 million in 2024, marking a 33% increase[231]. - Net cash used in investing activities for 2025 was $50.166 million, primarily due to the acquisition of Lehan for $26.3 million and capital expenditures of $23.8 million[234]. - The company’s principal source of liquidity is operating cash flow, supplemented by amounts available under the 2022 Senior Credit Facilities[238]. Acquisitions and Goodwill - The Company completed the acquisition of Lehan Drugs, Inc. on July 1, 2025, for a total consideration of approximately $29.2 million, resulting in goodwill of $25.9 million[316][317]. - Goodwill recognized from the acquisition of Lehan primarily represents expected operational synergies and strategic geographic expansion across the Midwest[319]. - The acquisition of Home Medical Products, Inc. on June 1, 2023, involved a cash payment of approximately $29 million, leading to goodwill of $29.8 million[321][322]. Assets and Liabilities - Total assets increased to $199.2 million in 2025 from $177.1 million in 2024, reflecting a growth of 12.5%[262]. - The company’s total liabilities increased to $55.6 million in 2025 from $43.8 million in 2024, marking a 26.9% rise[262]. - Total accrued liabilities rose to $23.9 million as of December 31, 2025, compared to $20.2 million in 2024[325]. - The Company’s debt under the 2022 Senior Credit Facilities increased to $12.9 million as of December 31, 2025, from $4.6 million in 2024[326]. Taxation - The Company recognized a provision for income taxes of $6.391 million for the year ended December 31, 2025, compared to $4.761 million in 2024 and $4.148 million in 2023[372]. - The effective tax rate for the Company was 29.4% for the years ended December 31, 2025 and 2024, and 28.8% for 2023[370]. - Total income taxes paid for the year ended December 31, 2025, amounted to $7,390 million, an increase from $6,827 million in 2024 and $3,566 million in 2023[374]. Stock and Share Repurchase - The company repurchased 1,976,441 common shares under the 2025 Share Repurchase Program, totaling $13.2 million[230]. - The Company authorized a share repurchase program on March 4, 2026, allowing for the repurchase of up to 1,930,131 shares effective through March 2027[380]. - The share repurchase program does not obligate the Company to acquire any specific number of shares and may be modified or discontinued at the Company's discretion[381].